# KRYSTAL-7 (NCT04613596)

> Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04613596
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Mirati Therapeutics Inc.
- Conditions: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
- Interventions: Adagrasib; Adagrasib; Adagrasib; Adagrasib; Pembrolizumab
- Enrollment: 626
- Primary outcome: Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.
- Primary outcome: Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab

## Indexed commentary on KRYSTAL-7 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 68
- YouTube: 12
- Podcasts: 11
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=krystal-7-nct04613596

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04613596", "email": "<work email>"}; the inbox owner confirms by the emailed link.